HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mycophenolate mofetil in the treatment of retroperitoneal fibrosis.

Abstract
The pathogenesis of idiopathic retroperitoneal fibrosis (IRPF) has been attributed to an autoimmune response to atherosclerotic lipid material leaking from blood vessels. Corticosteroids and cytotoxic agents have been used for therapy. Based on the immunosuppressive and anti-fibrotic action of mycophenolate, we administered this agent to a patient with biopsy-proven IRPF and achieved a rapid, complete and sustained remission with a 6-year follow-up.
AuthorsFareeha Khalil, M A Mir, Rocco C Venuto
JournalClinical rheumatology (Clin Rheumatol) Vol. 27 Issue 5 Pg. 679-81 (May 2008) ISSN: 0770-3198 [Print] Germany
PMID18185904 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Mycophenolic Acid
Topics
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Male
  • Middle Aged
  • Mycophenolic Acid (analogs & derivatives, therapeutic use)
  • Retroperitoneal Fibrosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: